|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||13.99 - 14.12|
|52 Week Range||12.48 - 18.43|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||16.45|
|Forward Dividend & Yield||0.37 (2.66%)|
|Ex-Dividend Date||Mar 27, 2020|
|1y Target Est||N/A|
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP0367/MA-0211 ("ASP0367") as a potential treatment for primary mitochondrial myopathies (PMM).
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, "Astellas") today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc. Tokyo, August 27, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Astellas Pharma Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.